Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27667184 | 1.00 | GAA (0.31) | GAALMNAL3MBTL1 | |
| SCHEMBL2636190 | 0.85 | CA12 (0.34) | — | |
| SCHEMBL999357 | 0.82 | ALDH1A1 (0.35) | LMNAL3MBTL1 | |
| SCHEMBL34474027 | 0.82 | GAA (0.30) | GAA | |
| SCHEMBL4338288 | 0.82 | LMNA (0.36) | LMNAL3MBTL1 | |
| SCHEMBL28758113 | 0.79 | USP2 (0.41) | LMNA | |
| SCHEMBL7556267 | 0.79 | USP2 (0.41) | LMNA | |
| SCHEMBL27686185 | 0.79 | LMNA (0.33) | LMNAL3MBTL1 | |
| SCHEMBL2635467 | 0.79 | LMNA (0.33) | LMNAL3MBTL1 | |
| SCHEMBL234252 | 0.78 | LMNA (0.36) | LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2438169-B1 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI | TOBIRA THERAPEUTICS INC (US) | 2017-08-09 | — | — | EP | disclosed |
| US-20150344533-A1 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI | TOBIRA THERAPEUTICS, INC. | 2015-12-03 | — | — | US | disclosed |
| US-20150247147-A1 | MODULATORS OF COAGULATION FACTORS | TOBIRA THERAPEUTICS, INC. | 2015-09-03 | — | — | US | disclosed |
| US-8889646-B2 | Nucleic acid modulators of glycoprotein VI | REGADO BIOSCIENCES, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8889645-B2 | Nucleic acid modulators of glycoprotein VI | REGADO BIOSCIENCES, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-8859518-B2 | Modulators of coagulation factors | REGADO BIOSCIENCES, INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-1745062-B1 | IMPROVED MODULATORS OF COAGULATION FACTORS | REGADO BIOSCIENCES INC (US) | 2014-06-04 | — | — | EP | disclosed |
| US-20140128587-A1 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI | REGADO BIOSCIENCES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128454-A1 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI | REGADO BIOSCIENCES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20130197065-A1 | Modulators of Coagulation Factors | REGADO BIOSCIENCES, INC. (US) | 2013-08-01 | — | — | US | disclosed |
| US-20100197900-A1 | MODULATORS OF COAGULATION FACTORS | REGADO BIOSCIENCES, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-7723315-B2 | A nucleic acid ligand whose sequence optionally includes a 2'-O-methyl modification and/or a 2'-O-fluoro modification, useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass | REGADO BIOSCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7531524-B2 | Modulators of coagulation factors with enhanced stability | REGADO BIOSCIENCES, INC. (US) | 2009-05-12 | — | — | US | disclosed |
| US-20080153769-A1 | A nucleic acid ligand whose sequence optionally includes a 2'-O-methyl modification and/or a 2'-O-fluoro modification, useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass | TOBIRA THERAPEUTICS, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080125383-A1 | For host undergoing surgery or coronary artery bypass | TOBIRA THERAPEUTICS, INC. | 2008-05-29 | — | — | US | disclosed |
| EP-1745062-A4 | IMPROVED MODULATORS OF COAGULATION FACTORS | REGADO BIOSCIENCES INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-7304041-B2 | Modulators of coagulation factors | REGADO BIOSCIENCES, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1745062-A2 | IMPROVED MODULATORS OF COAGULATION FACTORS | REGADO BIOSCIENCES, INC. (US) | 2007-01-24 | — | — | EP | disclosed |
| US-20060040881-A1 | A nucleic acid ligand whose sequence optionally includes a 2'-O-methyl modification and/or a 2'-O-fluoro modification, useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass. | TOBIRA THERAPEUTICS, INC. | 2006-02-23 | — | — | US | disclosed |
| WO-2005106042-A2 | IMPROVED MODULATORS OF COAGULATION FACTORS | REGADO BIOSCIENCES, INC. (US) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140128454-A1 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI | GP6, DNASE1L3, SELPLG | GAA 814/4885LMNA 524/4885L3MBTL1 3869/4885 |
| US-20150344533-A1 | NUCLEIC ACID MODULATORS OF GLYCOPROTEIN VI | GP6, DNASE1L3, SELPLG | GAA 814/4885LMNA 524/4885L3MBTL1 3869/4885 |
| US-20080125383-A1 | For host undergoing surgery or coronary artery bypass | NSUN2, SERPINC1, NSUN3 | GAA 1299/4885LMNA 1957/4885L3MBTL1 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.